CellThera AI

Executive Summary

CellThera AI is a privately held biotechnology company headquartered in Cambridge, MA, that leverages artificial intelligence and machine learning to engineer next-generation cell therapies for oncology and autoimmune diseases. Founded in 2021, the company has raised $70 million to build its proprietary AI platform that analyzes complex biological data to predict cell behavior and optimize therapeutic cell design. By integrating computational biology with synthetic biology, CellThera aims to accelerate the development of personalized, safer, and more effective cell treatments, addressing key limitations in traditional cell therapy manufacturing and efficacy. The company operates at the platform stage, focusing on validating its technology across multiple therapeutic areas before advancing into clinical development. With a strong emphasis on AI-driven discovery and design, CellThera positions itself as a key enabler in the rapidly evolving cell therapy landscape, targeting high unmet needs in cancer and autoimmune disorders.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnership with a top-10 pharmaceutical company for AI-driven target discovery in oncology75% success
• Q4 2026Release of in vivo proof-of-concept data for lead cell therapy candidate in autoimmune indication60% success
• Q1 2027Closing of Series B financing round of $50-80 million to fund pipeline expansion and platform validation80% success